Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Immix Biopharma, Inc.
| Metric | Immix Biopharma, Inc. IMMXHealthcare |
|---|---|
| Quality Score | 50 / 100 |
| Revenue (latest) | — |
| Net income (latest) | −$29M |
| Operating margin | — |
| Net margin | — |
| Return on equity | −31.4% |
| Return on assets | −28.1% |
| Return on capital (ROCE) | −31.6% |
| Debt / equity | 0.12× |
| Revenue growth (YoY) | — |
| Altman Z″ (distress) | 9.45 |
| Accruals / assets | −5.3% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.